

# Maria A Morozova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1319682/publications.pdf>

Version: 2024-02-01

5  
papers

70  
citations

2258059

3  
h-index

2272923

4  
g-index

5  
all docs

5  
docs citations

5  
times ranked

56  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. <i>Dermatology and Therapy</i> , 2021, 11, 1319-1332.	3.0	23
2	The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. <i>Inflammation Research</i> , 2021, 70, 1233-1246.	4.0	35
3	Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. <i>Vestnik Dermatologii I Venerologii</i> , 2021, 97, 80-91.	0.6	2
4	The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1340-1348.	0.8	0
5	Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 480-488.	1.0	10